Pharmacopeia
Master Compare
Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.
| Field |
DIGOXIN ANTIBODIES
Antidotes · Antidotes · Level 3
|
NALOXONE
Antidotes · Antidotes · Level 3
|
|---|---|---|
| Mechanism of action | Binds excess digoxin or digitoxin molecules circulating in the blood |
Reversal of MoP receptor effects such as sedation, hypotension, respiratory depression, and the dysphoric effects of partial agonists |
| Physiological effects | — | - CVS: > 0.3 mg/kg → ↑MAP |
| Absorption | - |
91% absorption but Oral BA 2% due to extensive first-pass metabolism |
| Protein binding | - |
46% |
| Volume of distribution | 0.3 L/kg [DigiFab] |
2 L/kg |
| Metabolism | Nil |
Liver |
| Excretion | Urine |
— |
| Clearance | — | 25 ml/min/kg |
| Half-life | Unbound: 11 hrs |
0.5-1.5 hrs |
| Adverse Effects Toxicity | Anaphylaxis – rare |
Rapid onset of withdrawal symptoms in opioid drug addiction |
| Chemical Pharmaceutics | Monoclonal antibody (mAB) FAB (Fragment antigen-binding) fragment from sheep immunized with digoxin derivative |
substituted oxymorphone derivative. |
| Class Group | Antidote |
Antidote |
| Indications Uses | - For treatment of acute and chronic digoxin overdose |
- the reversal of respiratory depression due to opioids |
| Legacy Cicm Level | Level 3 |
Level 3 |
| Main Action | Binds Digoxin Molecules |
competitive antagonist at mu-, delta-, |
| Onset Peak Duration | Onset: 0-60min |
Onset: 1-3 mins |
| Presentation | powder |
clear solution for injection containing 0.02/0.4 mg/ml of naloxone hydrochloride |
| Route And Dose | IV Empiric: 10vials of Fab fragments Known dose, no level: Known concentration: |
IV/IM - Reversal of post-operative respiratory depression and coma: 20-40mcg IV PRN |
| Special Points | — | effective in alleviating the pruritus, nausea, |